Alexion to Acquire Portola for ~$1.41B

 Alexion to Acquire Portola for ~$1.41B

Shots: Shots:

  • Alexion to acquire all shares of Portola’s common stock at $18/ share in cash with a premium of 132%. Alexion will be acquiring cash currently on Portola’s balance sheet, net of debt of ~$215M that will become due upon closing. The actual amounts will be determined following the closure of the transaction
  • The transaction is expected to be closed in Q3’20. The acquisition will expand Alexion’s hematology, neurology and critical care commercial portfolio with the addition of Portola’s Andexxa/ Ondexxya
  • Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya in EU, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the effects rivaroxaban and apixaban in severe and uncontrolled bleeding

Click here ­to­ read full press release/ article | Ref: Alexion | Image: Portola

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post